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clinical response to treatment and the number of QALYs per patient accrued during 
the study. Only direct medical costs (drug acquisition, administration and hospitali-
zation costs) were incorporated in the model, as the analysis was conducted from a 
third-party payer perspective. With respect to administration cost, two alternative 
scenarios were considered in the base case analysis: administration in day-case unit 
and administration in the hospital outpatient department. Probabilistic sensitivity 
analysis was conducted. Primary outcomes were quality adjusted life years (QALYs) 
and incremental cost-effectiveness ratios (ICER). Results: In the base case analysis, 
QALYs of FCM treated patients were higher compared to no iron treated patients by 
0.04 QALYs. The total 24-week cost of FCM was higher by € 969 and € 204, it the two 
scenarios respectively. This difference was mainly attributed to the administration 
cost and drug acquisition cost related to FMC. Incremental cost effectiveness analysis 
showed that treatment with FCM was a cost-effective option resulting in an ICER 
of € 25,506 and € 5,368 per QALY gained in the scenarios respectively. Probabilistic 
sensitivity analysis revealed that FCM was likely to be cost-effective in over 80% and 
99% in the two scenarios respectively, at a willingness-to-pay threshold of € 34,000 
per QALY gained. ConClusions: Ferric carboxymaltose may be a cost – effective 
option in relation to no iron treatment for the management of iron deficiency of HF 
patients in Greece.
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objeCtives: Non-adherence to drug therapy poses a significant problem in the treat-
ment of patients with presumed resistant hypertension (RH). It has been shown that 
therapeutic drug monitoring (TDM) is a useful tool for detecting non-adherence and 
identifying barriers to treatment adherence, leading to effective blood pressure (BP) 
control. However, the cost-effectiveness of TDM in the management of RH has not 
been investigated. Methods: A Markov model was used to evaluate life-years, qual-
ity-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in RH 
patients receiving either TDM optimized therapy or standard best medical therapy. 
The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. 
Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and 
mortality. Cost analyses were performed from a payer’s perspective. Deterministic 
and probabilistic sensitivity analyses were conducted. Results: In the age group 
of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at addi-
tional costs of € 3,854 and € 3,922, respectively. Given a willingness-to-pay threshold 
of € 35,000 per QALY gained, the probability of TDM being cost-effective was ≥ 95% in 
all age groups from 30 to 90 years. Results were influenced mostly by the frequency 
of TDM testing, the rate of non-responders to TDM, and the magnitude of effect of 
TDM on BP. ConClusions: Therapeutic drug monitoring presents a potentialy highly 
cost-effective health care intervention in patients diagnosed with RH. Importantly, 
this finding is valid for a wide range of patients, independent of gender and age.
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objeCtives: SHIFT trial demonstrated that, by decreasing heart rate with 
Ivabradine, the incidence of events is reduced in patients with HF due to left ven-
tricular systolic disfunction (LVSD) and heart rate (HR) over 70 bpm. A cost-effective-
ness analysis demonstrating that this treatment strategy is cost-effective in United 
Kingdom has been published, but there are no publications with Spanish data. The 
objetive of this analysis is to determine whether treatment with Ivabradine in HF 
due to LVSD is a cost-effective strategy in Spain. Methods: A Markov model with 
three health states was built (baseline, admission due to HF and death), based on a 
simulated cohort of patients suffering HF due to LVSD and HR over 70 bpm, in order 
to compare the treatment strategies of the SHIFT trial, Ivabradine vs placebo, on top 
of standard treatment, was performed. A cost-efectiveness analysis with a life-time 
horizon, under the perspective of the NHS. Spanish costs were used to feed the 
model, and it was assumed that quality of life was worse during hospitalizations. 
A probabilistic sensitivity analysis was performed. The model took into account 
the incidence of complications related with HF (admission for HF, readmission for 
HF and death) and was fed with transition probabilities taken from the SHIFT trial 
and the SHIFT-hospitalization trial. Costs were obtained from cost data bases, the 
National Statistics Institute of Spain, institutions and scientific journals. Results: 
Cost per QALY of Ivabradine in comparison to placebo in heart failure due to left 
ventricular systolic disfunction is € 17,488 € , well below the acceptability threshold 
accepted in our enviroment (around 30,000 € ). Cost per LYG was € 13,044. Results 
were robust in the performed sensitivity analyses. ConClusions: In conclusion, 
treatment with Ivabradine in heart failure due to left ventricular systolic dysfunc-
tion is cost-effective in Spain.
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objeCtives: The objective of this study was to evaluate the cost-effectiveness 
of apixaban in the prevention of thromboembolic events in patients with non-
valvular atrial fibrillation (NVAF) relatively to standard of care (warfarin or aspirin) 
from the Italian National Health System (SSN) perspective. Methods: A previ-
ously published Markov model was adapted for Italian NVAF patients. Clinical 
were each asked to review a different batch of ECGs with differing proportions of AF 
and Sinus Rhythm (SR). ECGs were presented to the reviewers on two separate occa-
sions in two variations: full 12 lead and 10-second rhythm strip only. The diagnoses 
(AF/SR or unsure) were compared to a Consultant Cardiologist reading the 12-lead 
ECG. Results: Overall, compared to the Consultant Cardiologist, the AF detection 
rate using a 12-lead ECG was 81% and 82% with a rhythm strip. There was a signifi-
cant difference (chi squared test, p< 0.01) in AF detection rate when the reviewers 
were divided into 2 groups according to level of cardiology experience. The AF detec-
tion rate for the 12-lead ECG amongst specialists vs. non-specialists was 93% vs. 
70% (P< 0.001) and 92% vs. 73% (P= 0.003) for the rhythm strip. ConClusions: Our 
findings indicate that a 10-second rhythm strip alone has a comparable AF detection 
rate to a 12-lead ECG in the hands of doctors and nurses when measured against the 
consultant’s diagnosis. With both the rhythm strip and a 12-lead ECG, the accuracy 
of AF detection improved with experience. Mass screening using a single strip could 
be acceptable and inexpensive particularly with mobile phone technology.
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objeCtives: Hemostatic agents are used to stop intraoperative bleeding in the 
presence of actively flowing blood when applied directly to the bleeding site. Recent 
published literature on animal studies and real-world outcome data indicated that 
the hemostatic matrix agent Floseal could stop bleedings and reduce complications 
more effectively than Surgiflo with thrombin. The objective of this study is to quan-
tify cost consequences in the Netherlands when using Floseal versus Surgiflo with 
thrombin from a hospital perspective. Methods: A cost-consequence model was 
built based on a large retrospective analysis of a Premier’s US Hospital database to 
assess the value of using Floseal to achieve hemostasis in mixed cardiac surgery pro-
cedures relative to Surgiflo with thrombin. The model captures the cost implications 
on the following parameters: (1) operating room time; (2) postoperative bleeding-
related complication rates; (3) the need for surgical revisions due to bleeding, and; 
(4) the number of intraoperative and postoperative blood transfusions. Costs (€ ) 
were derived from published literature, the Dutch guideline for cost research and 
2014 national list prices. The model assumed a surgical case load of 100 mixed 
cardiac surgeries. Results: By reducing operating time, but moreover the number 
of complications, surgical revisions and blood products transfusion, Floseal can 
lead to a cost saving of € 2,933 per patient in comparison to the use of Surgiflo with 
thrombin. ConClusions: Our preliminary analysis indicates that using Floseal to 
stop intraoperative bleeding could lead to significant cost saving for the hospitals in 
the Netherlands. Further studies are required to confirm these findings.
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objeCtives: To evaluate cost-effectiveness of dabigatran and new oral antico-
agulants (NOA) compared to currently reimbursed warfarin and low molecular 
weight heparins (LMWH) for thromboembolic events prophylaxis from a payer’s 
perspective in Colombia. Methods: Markov decision model based on efficacy, 
utilities and safety inputs from clinical trials (CT) (RE-COVER I and II; Einstein-
DVT; Einstein-PE; AMPLIFY; RE-SONATE; RE-MEDY and a meta-analysis of 18 CT 
for LMWH. Cost of medication was obtained from SISMED, Vademecum Med®, 
and government reference prices; costs of events were estimated from hospital 
billing records, POS tariffs, SOAT Manual and local experts. Costs are reported in 
euros (1 € = COP 2,655) and effectiveness in terms of deaths due to bleeding and 
Quality Adjusted Life Years (QALYs). A 3% discount rate was used for costs and 
QALYs. A cohort of 1,000 patients, with similar demographic characteristics to 
those reported in the CT, was followed for a 5-year time horizon; with analysis for 6 
months, 1 year and lifetime. A univariate and probabilistic sensitivity analysis was 
performed. Results: Deaths due to bleeding were 5 with dabigatran, 7 with apixa-
ban, 9 with LMWH, 7 with rivaroxaban and 15 with warfarin, per 10,000 patients. 
Dabigatran is dominant compared with LMWH and apixaban. Compared with 
rivaroxaban, dabigatran is safer with similar costs and QALYs gained. Considering 
a base line scenario comparing all alternatives versus warfarin, dabigatrán dem-
onstrates the lowest ICER (€ 32,121/QALY) compared with rivaroxaban (€ 36,388/
QALY), apixaban (€ 72,228/QALY) and LMWH (€ 604,515/QALY). Our findings were 
consistent in the sensitivity analyses. ConClusions: Dabigatran is the alter-
native with the best value for money when all alternatives are compared with 
warfarin, and is dominant compared with LMWH, which are reimbursed by the 
current Colombian National Plan POS.
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objeCtives: To evaluate the cost-effectiveness of iron repletion with ferric carboxy-
maltorse (FCM), in iron-deficient heart failure (HF) patients in Greece. Methods: 
An international economic model was locally adapted to evaluate the use ferric car-
boxymaltorse to standard care over a time horizon of 24 weeks corresponding to the 
duration of the FAIR-HF trial. The efficacy of therapy was evaluated based on the 
